newsfilter
← Latest News
GlobeNewswire·

Apollomics Reports First-Half 2026 Financial Results

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. FOSTER CITY, Calif., Nov. 09, 2026